DCA
GILD icon

DB&C Advisors’s Gilead Sciences GILD Stock Holding History

DB&C Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.63M Buy
12,865
+24
+0.2% +$3.16K 1.76% 18
2026
Q1 		$1.79M Buy
12,841
+58
+0.5% +$8.12K 2.33% 12
2025
Q4 		$1.57M Buy
+12,783
New +$1.55M 1.97% 16

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DB&C Advisors's GILD Position: Q2 2026 in Review

DB&C Advisors increased its Gilead Sciences (GILD) stake by 0.19% in Q2 2026, buying an estimated $3.16K and bringing the position to 12,865 shares worth $1.63M. The position accounts for 1.76% of the portfolio, ranked #18.

DB&C Advisors first reported a position in GILD in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.79M in Q1 2026. 2,271 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • DB&C Advisors held 12,865 shares of Gilead Sciences worth $1.63M as of Q2 2026.
  • DB&C Advisors bought 24 Gilead Sciences shares in Q2 2026, an estimated $3.16K.
  • Gilead Sciences made up 1.76% of DB&C Advisors's portfolio in Q2 2026, its #18 holding.
  • DB&C Advisors first reported a position in Gilead Sciences in Q4 2025 and has held it in 3 quarters since.
  • DB&C Advisors's Gilead Sciences position peaked at $1.79M in Q1 2026.
  • 2,271 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on DB&C Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.